Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis

Although biologics have revolutionized psoriasis treatment, they pose a significant burden on the healthcare budget. With the wide range of biologics available and the increasing number of biosimilars, insights into the real-world cost per responder (CPR) are required. Therefore, this study aims to evaluate the real-world CPR of adalimumab, ustekinumab, IL17- and IL23-inhibitors, incorporating both relative (Psoriasis Area and Severity Index; PASI75/90/100) and absolute (PASI ≤ 3/ ≤ 1) responder definitions and real-world dose adjustments. Tildrakizumab and bimekizumab were excluded due to limited data. Using Dutch list prices and discounts on adalimumab's and ustekinumab's originator prices because of biosimilar availability, adalimumab showed the lowest 1-year CPR across all responder definitions. Among biologics without biosimilar availability, the lowest CPRs were seen for brodalumab and guselkumab. Overall, the cost-per-PASI ≤ 3-responder was, across all biologics, more homogeneous than the CPR based on relative PASIs. Similar patterns were seen when using Swedish prices, which are, in contrast to Dutch prices, transparent. The relevance of using real-world data, specifically with the use of absolute PASIs instead of relative PASIs, is shown in this study. Additionally, as price fluctuations have the biggest impact on cost-effectiveness, price transparency is essential to effectively guide physicians in selecting a cost-effective treatment strategy.

Authors

Institutions

Publication Details

Journal
Acta Dermato Venereologica
Published
2025-06-18
DOI
https://doi.org/10.2340/actadv.v105.42767
Citations
1
Primary Topic
Biosimilars and Bioanalytical Methods
Type
article
Field-Weighted Citation Impact
0.80

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis

John E. M. Körver, W.P. Arnold, Femke M. Homan, J.M. Mommers et al.
1 citations
Acta Dermato Venereologica
Biosimilars and Bioanalytical Methods
0.80
article

Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis

John E. M. Körver, W.P. Arnold, Femke M. Homan, J.M. Mommers, Albert Duvetorp, Douwe Vellinga, A.M. Oostveen, Sharon R. P. Dodemont, A.L.A. Kuijpers, Marieke M.B. Seyger, Judith. H. J. Hendricksen-Roelofzen, Paul M. Ossenkoppele, Lizelotte J.M.T. Weppner‐Parren, Marisol E. Otero, M.A.M. Berends, Berit Velstra, Martijn B. A. van Doorn, E.M.G.J. de Jong, M. Birgitte Visch, Antoni Gostyński, Inge Marjet Haeck, Marloes M. Kleinpenning, Linda T.H. Godding, R.R.M.C. Keijsers, Ella A.M. van der Voort, Else N. Kop, J.M.P.A. van den Reek
article en
1 citations

Abstract

Although biologics have revolutionized psoriasis treatment, they pose a significant burden on the healthcare budget. With the wide range of biologics available and the increasing number of biosimilars, insights into the real-world cost per responder (CPR) are required. Therefore, this study aims to evaluate the real-world CPR of adalimumab, ustekinumab, IL17- and IL23-inhibitors, incorporating both relative (Psoriasis Area and Severity Index; PASI75/90/100) and absolute (PASI ≤ 3/ ≤ 1) responder definitions and real-world dose adjustments. Tildrakizumab and bimekizumab were excluded due to limited data. Using Dutch list prices and discounts on adalimumab's and ustekinumab's originator prices because of biosimilar availability, adalimumab showed the lowest 1-year CPR across all responder definitions. Among biologics without biosimilar availability, the lowest CPRs were seen for brodalumab and guselkumab. Overall, the cost-per-PASI ≤ 3-responder was, across all biologics, more homogeneous than the CPR based on relative PASIs. Similar patterns were seen when using Swedish prices, which are, in contrast to Dutch prices, transparent. The relevance of using real-world data, specifically with the use of absolute PASIs instead of relative PASIs, is shown in this study. Additionally, as price fluctuations have the biggest impact on cost-effectiveness, price transparency is essential to effectively guide physicians in selecting a cost-effective treatment strategy.

Acta Dermato VenereologicaVol. 105
University of Copenhagen (DK), Radboud University Nijmegen (NL), Lund University (SE), Maastricht University Medical Centre (NL), Gelre Hospitals (NL), Catharina Ziekenhuis (NL), Erasmus MC (NL), Radboud University Medical Center (NL), University Medical Center Utrecht (NL), Maastricht University (NL), Slingeland Ziekenhuis (NL), Alrijne Ziekenhuis (NL), St. Antonius Ziekenhuis (NL), Amphia Ziekenhuis (NL), Canisius-Wilhelmina Ziekenhuis (NL), Streekziekenhuis Koningin Beatrix (NL), Ziekenhuis Gelderse Vallei (NL), LEO Foundation (DK), Máxima Medisch Centrum (NL), Zuyderland Medisch Centrum (NL), Skåne University Hospital (SE), Ziekenhuis Groep Twente (NL), Rijnstate Hospital (NL), Ziekenhuis Bernhoven (NL), St. Anna Ziekenhuis (NL), Jeroen Bosch Ziekenhuis (NL), Bravis Ziekenhuis (NL), Maastro Clinic (NL), Erasmus University Rotterdam (NL)
Eli Lilly and Company, Pfizer, Sanofi, Regeneron Pharmaceuticals, LEO Pharma, Sanofi Genzyme, UCB Pharma
Partnerships for the goals
Openalex Percentile: Top 27%
Biosimilars and Bioanalytical Methods
0.80
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.